Sentences with phrase «of lung cancer patients with»

In the new study published in JAMA Oncology on June 4, Saad Khan, from the University of Texas Southwestern Medical Center, and colleagues said that a chunk of lung cancer patients with autoimmune disease are not eligible to receive the latest immunotherapy treatments.

For now, the current study shows that a significant population of lung cancer patients with HER2 mutations exists.

«As the population of the United States ages, there will be a higher number of lung cancer patients with comorbidities at diagnosis.»

Not exact matches

That leaves Merck largely free of competitors in the near - term in its quest to become a go - to, first - line option for lung cancer patients in combination with chemotherapy (Merck recently surprised investors with an early FDA filing for that combination).

That's not just because of Opdivo's failure — last month, Keytruda was shown to be better than standard chemotherapy in untreated advanced lung cancer patients with high levels of the PD - L1 protein, both stopping cancer progression and extending patients» lives.

The biotech specialist said that its updated phase 2 data in a study of its poziotinib candidate treatment for non-small cell lung cancer resulted in a preliminary confirmed objective response rate and potential progression - free survival benefit in patients with the EGFR Exon 20 Mutant form of the disease.

In a mid-stage trial, 16 of 37 lung cancer patients given a placebo ahead of standard chemo wound up hospitalized with severely low white blood cell counts.

She spoke at Genentech, a cancer research firm, exchanged e-mails with half a dozen other cancer patients nationwide and was interviewed on NPR as a voice of nonsmoker lung - cancer sufferers.

Geoff Oxnard, an assistant professor of medicine at Dana - Farber Cancer Institute and Harvard Medical School in Boston and one of Paweletz's collaborators, remarks that «I had a hospitalized patient last week, she's sick with metastatic lung cancer, and she's exactly the kind of patient who might have an [epithelial growth factor receptor (EGFR)-RSB- mutation, but I simply didn't have enough tissue to ask those questions yet.&Cancer Institute and Harvard Medical School in Boston and one of Paweletz's collaborators, remarks that «I had a hospitalized patient last week, she's sick with metastatic lung cancer, and she's exactly the kind of patient who might have an [epithelial growth factor receptor (EGFR)-RSB- mutation, but I simply didn't have enough tissue to ask those questions yet.&cancer, and she's exactly the kind of patient who might have an [epithelial growth factor receptor (EGFR)-RSB- mutation, but I simply didn't have enough tissue to ask those questions yet.»

Urbanic said the overall findings of the study suggest that there are some patients with recurrent lung cancers who can be treated with another definitive course of radiation therapy and still have a chance at a cure.

«One of the toughest challenges of lung cancer is what to do for patients when the cancer comes back in an area that's been treated previously with radiation treatment,» said James J. Urbanic, M.D., lead author of the studies and a radiation oncologist at Wake Forest Baptist.

Approximately one year after successful treatment with cytotoxic chemotherapy and radiotherapy, patients with advanced Small Cell Lung Cancer (SCLC), which primarily affects heavy smokers, generally relapse with recurrence of tumours that are resistant to further chemotherapy.

Additionally, lung cancer patients who have high levels of YAP1 in their tumors are more likely to have a poorer prognosis than patients with low levels of YAP1.

If hypofractionated radiation with curative intent can reduce the treatment time for lung cancer patients by half with no greater toxicity, and with equivalent — if not better — tumor control and survival outcomes, this research could result in a change in the paradigm of how a large subset of locally advanced NSCLC patients are treated.»

For example, lung cancer patients who were injected with killed M. vaccae reported better quality of life and less nausea and pain.

Patients with metastatic non-small cell lung cancer will always progress after chemotherapy, so most patients go on to be treated with immunotherapy, a type of therapy that uses the body's immune system to fightPatients with metastatic non-small cell lung cancer will always progress after chemotherapy, so most patients go on to be treated with immunotherapy, a type of therapy that uses the body's immune system to fightpatients go on to be treated with immunotherapy, a type of therapy that uses the body's immune system to fight cancer.

Led by associate professor of pathology and Yale Cancer Center member Don Nguyen, PhD, the researchers analyzed RNA from patients with disease that was limited to the lungs as well as cancers that had spread.

Findings were presented at the WCLC are based on the updated results of 12 lung cancer patients enrolled in the clinical trial with pembro and irinotecan or gemcitabine with or without vinorelbine or docetaxel.

The researchers combined data from lung cancer patients in The Society of Thoracic Surgeons (STS) General Thoracic Surgery Database (GTSD) with claims data from the Centers for Medicare & Medicaid Services (CMS).

According to the National Cancer Institute, the 5 - year survival of all patients diagnosed with lung cancer in the United States is approximatelyCancer Institute, the 5 - year survival of all patients diagnosed with lung cancer in the United States is approximatelycancer in the United States is approximately 17 %.

«Blocking both of these proteins could be a treatment that is beneficial for the majority of lung cancer patients,» said Dr. Habib, Associate Professor of Neurology and Neurotherapeutics with UT Southwestern's Peter O'Donnell Jr..

The drug erlotinib is prescribed to between 10 — 30 per cent of patients with non-small cell lung cancer, which accounts for 85 per cent of all lung cancer cases.

These studies enrolled a total of 12,361 patients diagnosed with a variety of cancers, including lung, breast, skin, and prostate, as well as blood cancers such as leukemia, lymphoma, and myeloma.

«Our findings suggest that this new drug combination would also help patients with this type of aggressive breast cancer as well as other cancers, such as lung, prostate and ovarian cancers,» Dr. Rassool says.

Patients aged 65 years and older are living longer after lung cancer surgery, and with older people representing a rapidly growing proportion of patients diagnosed with lung cancer, this improved survival is especially significant, according to an article posted online today by The Annals of Thoracic SPatients aged 65 years and older are living longer after lung cancer surgery, and with older people representing a rapidly growing proportion of patients diagnosed with lung cancer, this improved survival is especially significant, according to an article posted online today by The Annals of Thoracic Spatients diagnosed with lung cancer, this improved survival is especially significant, according to an article posted online today by The Annals of Thoracic Surgery..

Immunotherapy with a live bacterium combined with chemotherapy demonstrated more than 90 % disease control and 59 % response rate in patients with malignant pleural mesothelioma (MPM), according to the results of a phase Ib trial presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland.1

PET scans showed dramatically increased glucose metabolism in the lungs of 20 immune - compromised pediatric cancer patients with flu and other respiratory infections compared to patients without infections.

The approach is already routine for some cancer patients, such as women and men with breast cancer tumors that have high levels of a protein called HER2, or lung cancer tumors with mutations in the EGFR gene.

«Although some non-small cell lung cancer patients have increased benefit of targeted therapy or immunotherapy instead of chemotherapy, for some groups of patients with NSNSCLC, chemotherapy has been the standard treatment for more than 30 years,» Gandhi notes.

Researchers only discovered this process in the late 1990s, but they've already begun dozens of clinical trials to gauge whether infusing patients with these small RNAs works against a range of diseases, from lung infections to liver cancer to age - related macular degeneration, a sight - stealing condition that mainly affects people over the age of 50.

Identification of a specific genetic mutation in patients with non-small-cell lung cancer (NSCLC) helps clinicians select the best treatment option.

A drug approved by the Food and Drug Administration (FDA) for melanoma in combination with a common cholesterol - lowering drug may show promise in controlling cancer growth in patients with non-small cell lung cancer (NSCLC), according to new research from the Icahn School of Medicine at Mount Sinai.

Among patients with non-small cell lung cancer (NSCLC) fueled by ALK gene alterations who were being treated with crizotinib (Xalkori), a decrease in the number of circulating tumor cells (CTCs) harboring increased copies of the ALK gene over the first two months of treatment was associated with increased progression - free survival.

Phase I / II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK + non-small cell lung cancer (NSCLC), with 58 of 78 ALK + patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor.

Italian researches have demonstrated a better way of determining the aggressiveness of tumors in patients with advanced non-small cell lung cancer (NSCLC).

Many lung cancer trials have traditionally excluded patients with brain metastases at baseline, expecting that the presence of metastases would create negative results that could in turn create the appearance of drug failure.

Combining radiation therapy with chemotherapy for patients with limited metastatic non-small cell lung cancer (NSCLC) may curb disease progression dramatically when compared to NSCLC patients who only receive chemotherapy, according to a new randomized phase II clinical trial reported today at the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO).

After a median follow - up of 11 months, 11 of the 13 patients who responded remain on the study, including one patient who had non-small cell lung cancer (NSCLC) with a ROS1 gene fusion who has had a complete response that has been maintained for more than two years.

For the study, Gabriella Hobbs, MD, and Nancy Keating, MD, MPH, of Harvard Medical School, and their colleagues surveyed 5284 patients with a new diagnosis of lung or colon cancer, and asked participants how they involved their families in decisions about their care.

Some patients with non-small cell lung cancer (NSCLC) have changes in the anaplastic lymphoma kinase (ALK) gene, which can drive the development of their cancer.

Among patients with advanced non-small cell lung cancer without a mutation of a certain gene (EGFR), conventional chemotherapy, compared with treatment using epidermal growth factor receptor tyrosine kinase inhibitors, was associated with improvement in survival without progression of the cancer, but not with overall survival, according to a study in the April 9 issue of JAMA.

They also chose to study a type of K - Ras mutant called G12C (for Glycine - 12 to Cysteine), a K - Ras mutant prevalent in about seven percent of patients with lung cancer.

Around 1,600 people are diagnosed with non-small cell lung cancer in Greater Manchester every year and a proportion of these patients will have the ALK - positive type.

The team found that patients with breast, gastric or lung cancers survived longer when they had higher levels of Bmal1 protein.

Pembrolizumab is set to become a new option for first line treatment of patients with advanced lung cancer and high PD - L1 expression, according to the results of the phase III KEYNOTE - 024 trial presented at the ESMO 2016 Congress in Copenhagen and published in the New England Journal of Medicine.

Now doctors have investigated the use of crizotinib in patients with ALK positive lung cancer who have not yet received any chemotherapy treatment.

Epidermal growth factor receptor (EGFR) mutations found in the circulating free tumor DNA (ctDNA) from the plasma of advanced non-small cell lung cancer (NSCLC) patients correlates well with the EGFR mutations from patient - matched tumor tissue DNA.

Commenting on the findings, Prof Robert Pirker, programme director for lung cancer at the Vienna General Hospital in Vienna, Austria, not involved in the study, said: «This subgroup analysis shows that the effect of necitumumab was slightly greater in patients with EGFR expressing tumours than it was in the entire SQUIRE population.

Research from McMaster University has identified new regulators of brain metastases in patients with lung cancer.

Trinh and his colleagues used Surveillance, Epidemiology, and End Results Program (SEER) data to look at more than 2.5 million Asian American patients who were diagnosed with lung, breast, prostate or colorectal cancer (the three leading causes of cancer - related mortality within each gender) between 1991 and 2007.